Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 528 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) February 7, 2019 Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... November 14, 2019 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... October 11, 2019 Load more HOT NEWS Early-onset cancer: why are more young adults being diagnosed? Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update. Man Who Lost Wife to Breast Cancer Wants to Donate Her... Peer-to-peer match-funding initiative raises over £4 million for cancer research
